144 related articles for article (PubMed ID: 29601247)
1. An update on treatment for post-menopausal metastatic breast cancer in elderly patients.
Menjak IB; Jerzak KJ; Desautels DN; Pritchard KI
Expert Opin Pharmacother; 2018 Apr; 19(6):597-609. PubMed ID: 29601247
[TBL] [Abstract][Full Text] [Related]
2. An update on adjuvant systemic therapy for elderly patients with early breast cancer.
Jerzak KJ; Desautels DN; Pritchard KI
Expert Opin Pharmacother; 2016 Oct; 17(14):1881-8. PubMed ID: 27539883
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
4. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
[TBL] [Abstract][Full Text] [Related]
5. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
6. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
7. Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
Poggio F; Lambertini M; Blondeaux E; Vaglica M; Levaggi A; Pronzato P; Del Mastro L
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1153-61. PubMed ID: 27545815
[TBL] [Abstract][Full Text] [Related]
8. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
10. Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer.
Flaum LE; Gradishar WJ
Cancer Treat Res; 2018; 173():141-154. PubMed ID: 29349762
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
[TBL] [Abstract][Full Text] [Related]
12. Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.
Montemurro F; Rossi V; Geuna E; Valabrega G; Martinello R; Milani A; Aglietta M
Expert Opin Pharmacother; 2012 Oct; 13(15):2143-56. PubMed ID: 22984936
[TBL] [Abstract][Full Text] [Related]
13. [Progress in second-line therapies for metastatic breast cancer].
Shigekawa T; Osaki A; Saeki T
Gan To Kagaku Ryoho; 2015 Apr; 42(4):408-15. PubMed ID: 25963688
[TBL] [Abstract][Full Text] [Related]
14. The safety of palbociclib for the treatment of advanced breast cancer.
Degenhardt T; Wuerstlein R; Eggersmann T; Harbeck N
Expert Opin Drug Saf; 2018 Mar; 17(3):325-330. PubMed ID: 29338448
[TBL] [Abstract][Full Text] [Related]
15. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
16. [Effective treatment strategy in elderly breast cancer patients].
Boér K
Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
[TBL] [Abstract][Full Text] [Related]
17. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
[TBL] [Abstract][Full Text] [Related]
18. An update on first line therapies for metastatic breast cancer.
Fedele P; Ciccarese M; Surico G; Cinieri S
Expert Opin Pharmacother; 2018 Feb; 19(3):243-252. PubMed ID: 29336185
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns.
Abdel-Rahman O; ElHalawani H
Expert Opin Drug Saf; 2014 Nov; 13(11):1443-67. PubMed ID: 25244502
[TBL] [Abstract][Full Text] [Related]
20. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
